Nihilism No More: The 2021 ATA Anaplastic Thyroid Cancer Guidelines-Reference-Cited by-同舟云学术

Nihilism No More: The 2021 ATA Anaplastic Thyroid Cancer Guidelines

Published:2021-05-01 Issue:5 Volume:33 Page:229-233
ISSN:2329-9711
Container-title:Clinical Thyroidology
language:en
Short-container-title:Clinical Thyroidology

Author:

Pasternak Jesse D.¹,Angell Trevor E.²,Lorch Jochen³

Affiliation:

1. Department of Surgery, University Health Network and University of Toronto, Toronto, Canada

2. Division of Endocrinology and Diabetes, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, U.S.A.

3. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, U.S.A.

Publisher

Mary Ann Liebert Inc

Subject

General Engineering

Link

https://www.liebertpub.com/doi/pdf/10.1089/ct.2021%3B33.229-234

Reference11 articles.

1. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

2. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

3. PD-1 Blockade in Anaplastic Thyroid Carcinoma

4. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).

5. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma;JCO Precision Oncology;2022-08